-
Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004
•
Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a $60 million payment from AstraZeneca (AZ, NASDAQ: AZN) following the successful achievement of development milestones for ECC5004/AZD5004, including the dosing of the first patient in the Phase 2b trial. This payment is a part of…
-
Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004
•
Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will take over the development and commercialization rights to Eccogene’s GLP-1 receptor agonist drug candidate, ECC5004, for the treatment of obesity, type 2 diabetes,…
-
Eccogene Secures $25 Million in Series B Financing to Advance Metabolic Disease Therapies
•
Sino-US firm Eccogene Inc. has announced the closure of a Series B financing round, raising RMB180 million (USD 25 million). The round was co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, with participation from new investors Rockbleu Capital, YuFu Investment, Huajin Capital, and Elikon Venture, as well as…
-
Eccogene Gains FDA Approval for Phase I Study of ECC5004
•
Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I clinical study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ECC5004, a glucagon-like peptide 1 receptor agonist (GLP-1 RA) targeting type 2 diabetes mellitus (T2DM), in healthy participants and subjects with T2DM. GLP-1 Mechanism and…
-
Eccogene Receives FDA Approval for ECC4703 Phase I Study in NASH and Dyslipidemia
•
Shanghai-based biopharmaceutical company Eccogene announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial for ECC4703, a thyroid hormone receptor (THR) agonist. The study will assess the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and subjects with elevated…
